OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland
07 juin 2021 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., June 07, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen Reports First Quarter 2021 Financial Results and Provides Business Update
13 mai 2021 07h30 HE
|
OpGen, Inc.
Total Revenue for Q1 2021 was approximately $0.8 millionBalance sheet strengthened significantly with an additional $34.7 million cash raised in Q1 2021 Conference call to be held at 8:30 a.m....
OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time
29 avr. 2021 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first...
OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections
19 avr. 2021 07h30 HE
|
OpGen, Inc.
Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021 Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse®...
OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients
12 avr. 2021 07h30 HE
|
OpGen, Inc.
Experts presented the results of their Unyvero studies and demonstrated: Distinguishing those COVID-19 ICU patients with bacterial superinfection early and accurately is crucial for patient...
OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
25 mars 2021 16h01 HE
|
OpGen, Inc.
Total combined pro-forma revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.4 million cash as of December 31, 2020 Raised an additional $34.7 million of capital...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020
11 mars 2021 07h30 HE
|
OpGen, Inc.
GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth...
OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia
08 mars 2021 07h30 HE
|
OpGen, Inc.
Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients High negative...
OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System
01 mars 2021 07h30 HE
|
OpGen, Inc.
Chinese regulatory authority NMPA completes registration of Unyvero instrument system as IVD for Chinese marketApplication of Unyvero cartridge for pneumonia is under review and pending NMPA...
OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing
16 févr. 2021 07h30 HE
|
OpGen, Inc.
Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data Publication supports harmonization of the development of good machine...